# Management of Progressive Disease in Idiopathic Pulmonary Fibrosis

> **NCT03939520** · PHASE4 · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 279 (actual)

## Conditions studied

- Progressive Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** pirfenidone and nintedanib
- **DRUG:** pirfenidone or nintedanib
- **DRUG:** pirfenidone or nintedanib

## Key facts

- **NCT ID:** NCT03939520
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-11
- **Primary completion:** 2026-01-09
- **Final completion:** 2026-01-09
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03939520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03939520, "Management of Progressive Disease in Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03939520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*